Therapeutic challenges posed by bacterial bioterrorism threats.
The events of the autumn of 2001 in the United States made it clear that the spectre of the use of microorganisms to intentionally harm humans is a reality. The current strategy to control disease outbreaks caused by the intentional release of bacteria is to use antimicrobial agents, both therapeutically and prophylactically. However, multidrug-resistant strains of bacterial bioterrorism agents occur naturally or have been bio-engineered, indicating how vulnerable this strategy is.
D000881:Anthrax / Q000188:drug therapy / Q000517:prevention & control; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001419:Bacteria / Q000187:drug effects; D001424:Bacterial Infections / Q000188:drug therapy* / Q000517:prevention & control; D023482:Bioterrorism / Q000517:prevention & control; D003140:Communicable Disease Control / Q000379:methods; D003141:Communicable Diseases / Q000188:drug therapy / Q000635:transmission; D004196:Disease Outbreaks / Q000145:classification / Q000517:prevention & control*; D004352:Drug Resistance, Microbial; D006801:Humans; D010930:Plague / Q000188:drug therapy / Q000517:prevention & control; D011634:Public Health
D000900:Anti-Bacterial Agents